<DOC>
	<DOC>NCT02310009</DOC>
	<brief_summary>Subjects (N=48) with poorly-controlled type 2 diabetes (HbA1c&gt;7%) will be assigned to one of the 4 following interventions in a randomised, parallel group design: [I] Control (placebo injection; no exercise), [II] Anakinra (100 mg subcutaneous injection of human recombinant interleukin-1 receptor antagonist), [III] Exercise (1 h cycle ergometry at 75% VO2max), [IV] Anakinra + Exercise. Pancreatic beta-cell function (plasma insulin responses) will be measured before and after each intervention using a hyperglycemic clamp (5.4 mM above basal glucose) combined with GLP-1 infusion (0.5 pmol/kg/min) and arginine injection (5 g bolus).</brief_summary>
	<brief_title>IL-1RA, Acute Exercise, and Beta-cell Function</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Interleukin 1 Receptor Antagonist Protein</mesh_term>
	<criteria>Type 2 diabetes with HbA1c &gt;7% HbA1c &gt;7% Age &lt;30 or &gt;80 y BMI &lt;25 or &gt;40 kg/m2 Pregnancy Evidence of chronic haematological/renal/hepatic/pulmonary/heart disease &gt;2kg weight change in prior 6 months Alcohol consumption (men: &gt;14 drinks/week; women: &gt;7 drinks/week) Smoking Physical activity of &gt;150 min/week Contraindication to exercise Contraindication to use of anakinra</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Exercise</keyword>
	<keyword>IL-1RA</keyword>
	<keyword>Beta-cell function</keyword>
	<keyword>Type 2 Diabetes</keyword>
</DOC>